Lior Carmon
Chief Investment Officer at Van Leer Xenia Ventures
Profile
Lior Carmon is the founder of Vaxil Bio Ltd.
which was founded in 2006, where he held the titles of CEO, Director, and Head-Research & Development.
He is currently a Director at Israel Immunological Society, Saqura Bio Ltd.
(since 2022), and Chief Investment Officer at Van Leer Xenia Ventures.
Dr. Carmon's former position was as a Director at Vaxil Bio Ltd.
Dr. Carmon holds an MBA from Ben-Gurion University of the Negev and a doctorate from Weizmann Institute of Science.
Lior Carmon active positions
Companies | Position | Start |
---|---|---|
Israel Immunological Society | Director/Board Member | - |
Van Leer Xenia Ventures
Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Chief Investment Officer | - |
Sakura Bio
Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Director/Board Member | 2022-09-30 |
Former positions of Lior Carmon
Companies | Position | End |
---|---|---|
VAXIL BIO LTD. | Director/Board Member | 2017-01-03 |
Vaxil Bio Ltd. /Old/
Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Chief Executive Officer | - |
Training of Lior Carmon
Ben-Gurion University of the Negev | Masters Business Admin |
Weizmann Institute of Science | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
VAXIL BIO LTD. | Health Technology |
Private companies | 4 |
---|---|
Vaxil Bio Ltd. /Old/
Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Health Technology |
Israel Immunological Society | |
Van Leer Xenia Ventures
Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Finance |
Sakura Bio
Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Lior Carmon